The plaintiffs do not prescribe or use mifepristone.
And FDA is not requiring them to do or refrain from doing anything.
A plaintiffs desire to make a drug less available for others does not establish standing to sue.
Getty Images
Nor do the plaintiffs other standing theories suffice.
Therefore, the plaintiffs lack standing to challenge FDAs actions.
Medical experts and health care providers applauded the courts decision to uphold access to mifepristone.
Mifepristone was first approved by the FDA in 2000.
But things changed quickly.
This put telemedicine access to the pill in jeopardy.
This decision demonstrates that the Supreme Court understood how destabilizing it would be to undermine the FDAs authority.
This storywas originally publishedinWired.
